Selecta Biosciences Inc expected to post a loss of 6 cents a share - Earnings Preview

Cartesian Therapeutics

30/10/2023 18:33

* Selecta Biosciences Inc  SELB.OQ   SELB.O  is expected
to show a
fall in quarterly revenue when it reports  results 
    * The Watertown Massachusetts-based  company is expected to
report
 a 46.8% decrease in revenue to $11.025 million from $20.71
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Selecta Biosciences
Inc
is for a loss of 6 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Selecta
Biosciences Inc is $4​, above​ its last closing price of $1.23.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.08       -0.08      -0.07     Beat    12.5
 Mar. 31 2023  -0.09       -0.09      -0.14     Missed  -60.7
 Dec. 31 2022  -0.08       -0.07      0.04      Beat    154.9​
 Sep. 30 2022  0.03        -0.01      -0.05     Missed  -775.7
 ​​Jun.        -0.06       -0.08      0.06      Beat    177.8
 30 2022                                                
 Mar. 31 2022  -0.10       -0.11      0.23      Beat    312.3​
 Dec. 31 2021  -0.08       -0.07      0.03      Beat    141.2
 Sep. 30 2021  -0.03       -0.07      -0.16     Missed  -115.4
 This summary was machine generated October 30 at 18:33 GMT.  All
figures in US dollars  unless otherwise stated